M. Roffi et al., Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with Non-ST-segment-elevation acute coronary syndromes, CIRCULATION, 104(23), 2001, pp. 2767-2771
Citations number
31
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Background-Diabetes mellitus is a major risk factor for adverse outcomes af
ter acute coronary syndromes (ACS). Because this disease may be associated
with increased platelet aggregation, we investigated whether diabetic patie
nts with ACS derive particular benefit from platelet glycoprotein (GP) IIb/
IIIa receptor inhibition.
Methods and Results-We performed a meta-analysis of the diabetic population
s enrolled in the 6 large-scale platelet GP IIb/IIIa inhibitor ACS trials:
PRISM, PRISM-PLUS, PARAGON A, PARAGON B, PURSUIT, and GUSTO IV. Among 6458
diabetic patients, platelet GP IIb/IIIa inhibition was associated with a si
gnificant mortality reduction at 30 days, from 6.2% to 4.6% (OR 0.74; 95% C
I 0.59 to 0.92; P = 0.007). Conversely, 23072 nondiabetic patients had no s
urvival benefit (3.0% versus 3.0%). The interaction between platelet GP IIb
/IIIa inhibition and diabetic status was statistically significant (P = 0.0
36). Among 1279 diabetic patients undergoing percutaneous coronary interven
tion (PCI) during index hospitalization, the use of these agents was associ
ated with a mortality reduction at 30 days from 4.0% to 1.2% (OR 0.30; 95%
Cl 0.14 to 0.69; P = 0.002).
Conclusions-This meta-analysis, including the entire large-scale trial expe
rience of intravenous platelet GP IIb/IIIa inhibitors for the medical manag
ement of non-ST-segment-clevation ACS, shows that these agents may signific
antly reduce mortality at 30 days in diabetic patients. Although not based
on a randomized assessment, the survival benefit appears to be of greater m
agnitude in patients undergoing PCI. Therefore, the use of platelet GP IIb/
IIIa inhibitors should be strongly considered in diabetic patients with ACS
.